Allspring Global Investments Holdings LLC Increases Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Allspring Global Investments Holdings LLC increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 55.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 191,476 shares of the medical equipment provider's stock after acquiring an additional 68,361 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.28% of Lantheus worth $21,015,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in LNTH. Mitsubishi UFJ Asset Management UK Ltd. boosted its position in shares of Lantheus by 250.0% during the third quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 9,800 shares of the medical equipment provider's stock valued at $1,076,000 after purchasing an additional 7,000 shares in the last quarter. Net Worth Advisory Group bought a new stake in shares of Lantheus during the 3rd quarter valued at $218,000. Stratos Wealth Advisors LLC grew its position in shares of Lantheus by 3.8% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 21,863 shares of the medical equipment provider's stock worth $2,399,000 after buying an additional 809 shares during the period. AlphaMark Advisors LLC increased its stake in shares of Lantheus by 556.5% in the 3rd quarter. AlphaMark Advisors LLC now owns 3,578 shares of the medical equipment provider's stock worth $393,000 after acquiring an additional 3,033 shares in the last quarter. Finally, Bleakley Financial Group LLC purchased a new position in Lantheus during the 3rd quarter valued at about $231,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LNTH. JMP Securities dropped their price target on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 1st. B. Riley lifted their price target on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Truist Financial cut their price objective on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research report on Thursday, August 1st. Leerink Partners lifted their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a report on Thursday, July 11th. Finally, Redburn Atlantic began coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target on the stock. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus has a consensus rating of "Moderate Buy" and an average price target of $126.00.

Lantheus Price Performance

LNTH traded up $0.49 during trading hours on Friday, hitting $110.30. The company's stock had a trading volume of 375,626 shares, compared to its average volume of 962,166. The stock has a market cap of $7.66 billion, a price-to-earnings ratio of 17.96 and a beta of 0.50. The business's 50-day moving average price is $107.02 and its 200-day moving average price is $92.35. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. During the same period in the previous year, the business posted $1.40 EPS. The firm's revenue was up 22.5% on a year-over-year basis. Sell-side analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, President Paul Blanchfield sold 2,000 shares of the company's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now owns 98,980 shares of the company's stock, valued at approximately $9,540,682.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Mary Anne Heino sold 10,481 shares of the firm's stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the transaction, the director now directly owns 454,923 shares of the company's stock, valued at approximately $43,445,146.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Paul Blanchfield sold 2,000 shares of the business's stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company's stock, valued at $9,540,682.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,981 shares of company stock valued at $2,689,156 over the last three months. 1.50% of the stock is owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.